Two-stage design and 'forced bioequivalence' [Two-Stage / GS Designs]

posted by Mikalai  – Belarus, 2018-06-06 10:28 (2478 d 13:12 ago) – Posting: # 18854
Views: 7,090

Dear all,
We plan to conduct a sequential (two stage) BE study, and I am concerned with "forced bioequivalence". Specifically, if we obtain non-equivalent results in the first stage with very low power and should recruit more volunteers, how can we protect ourselves from getting into "forced bioequivalence"? In other words, how can we differentiate between underpowered trials and non-equivalent results in the sequential BE? And how can we put this (protection against "forced bioequivalence") in the protocol not to raise many questions from regulators?
Any suggestions and advice will be appreciated.
Sincerely,
Mikalai

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,670 registered users;
18 visitors (0 registered, 18 guests [including 8 identified bots]).
Forum time: 22:40 CET (Europe/Vienna)

There are no such things as applied sciences,
only applications of science.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5